Time to recovery · patients diagnosed with clinical and laboratory‐confirmed diagnosis of infectious mononucleosis (glandular fever)
1 finding from 1 review
Time to clinical recovery patient judgement · patients diagnosed with clinical and laboratory‐confirmed diagnosis of infectious mononucleosis (glandular fever)
1 finding from 1 review
Side effects or other adverse events · patients diagnosed with clinical and laboratory‐confirmed diagnosis of infectious mononucleosis (glandular fever)
1 finding from 1 review
Duration of lymphadenopathy · patients diagnosed with clinical and laboratory‐confirmed diagnosis of infectious mononucleosis (glandular fever)
1 finding from 1 review
Development of complications of Infectious mononucleosis · patients diagnosed with clinical and laboratory‐confirmed diagnosis of infectious mononucleosis (glandular fever)
1 finding from 1 review
Viral shedding · patients diagnosed with clinical and laboratory‐confirmed diagnosis of infectious mononucleosis (glandular fever)
1 finding from 1 review
Days missed from work or school · patients diagnosed with clinical and laboratory‐confirmed diagnosis of infectious mononucleosis (glandular fever)
1 finding from 1 review
All‐cause mortality maximum · adults with chronic hepatitis C
It is very uncertain whether direct‐acting antivirals changes all‐cause mortality at maximum compared with control (very low certainty).
1 finding from 1 review
Proportion of participants with one or more serious adverse event at maximum · adults with chronic hepatitis C
It is very uncertain whether direct‐acting antivirals changes proportion of participants with one or more serious adverse event at… compared with control (very low certainty).
1 finding from 1 review
Proportion of participants with no sustained virological response at maximum · adults with chronic hepatitis C
Direct‐acting antivirals may leads to lower proportion of participants with no sustained virological response at… compared with control (low certainty).
1 finding from 1 review
All‐cause mortality maximum · adults with chronic hepatitis C
It is very uncertain whether direct‐acting antivirals withdrawn from the market changes all‐cause mortality at maximum compared with control (very low certainty).
1 finding from 1 review
Proportion of participants with one or more serious adverse event at maximum · adults with chronic hepatitis C
It is very uncertain whether direct‐acting antivirals withdrawn from the market changes proportion of participants with one or more serious adverse event at… compared with control (very low certainty).
1 finding from 1 review
Proportion of participants with no sustained virological response at maximum · adults with chronic hepatitis C
Direct‐acting antivirals withdrawn from the market may leads to lower proportion of participants with no sustained virological response at… compared with control (low certainty).
1 finding from 1 review
Incomplete recovery at end of study № of participants: 766 (3 RCTs) · Bell's palsy
Antivirals plus corticosteroids showed no clear difference in incomplete recovery at end of study № of participants: 766 (3 RCTs) compared with corticosteroids plus placebo or no treatment (AS versus OS) (low certainty).
1 finding from 1 review
RR 0.81 [0.38, 1.74]
Studies not reported
Low
Motor synkinesis or crocodile tears № of participants: 469 (2 RCTs) · Bell's palsy
Antivirals plus corticosteroids probably leads to lower motor synkinesis or crocodile tears № of participants: 469 (2 RCTs) compared with corticosteroids plus placebo or no treatment (AS versus OS) (moderate certainty).
1 finding from 1 review
RR 0.56 [0.36, 0.87]
Studies not reported
Moderate
Adverse events № of participants: 656 (2 RCTs) · Bell's palsy
It is very uncertain whether antivirals plus corticosteroids changes adverse events № of participants: 656 (2 RCTs) compared with corticosteroids plus placebo or no treatment (AS versus OS) (very low certainty).
1 finding from 1 review
RR 1.17 [0.81, 1.68]
Studies not reported
Very low
Death · patients on HD with HCV infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Relapse · patients on HD with HCV infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
End‐of‐treatment response · patients on HD with HCV infection
Direct antivirals (grazoprevir and elbasvir) may leads to higher end‐of‐treatment response compared with placebo (low certainty).
1 finding from 1 review
Sustained virological response · patients on HD with HCV infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found